Interferons in neurology;Interferones en neurología

Revista de Investigacion Clinica

Volumn 52, Issue 6, 2000, Pages 665-679

  Rebolledo, F A ^a  

^a Unidad de Invest en Epidemiol   (Mexico)

Author keywords

Biologic mechanism; Indications; Interferons; Kurtzke scale; Multiple sclerosis

Indexed keywords

BACLOFEN; BETA1A INTERFERON; GAMMA INTERFERON; HLA DQ ANTIGEN; HLA DR2 ANTIGEN; INTERFERON; INTERFERON BETA SERINE; LYMPHOBLAST INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENTOXIFYLLINE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ALOPECIA; CHRONIC HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEVER; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INSOMNIA; KAPOSI SARCOMA; LEUKEMIA; LYMPHOMA; MENSTRUATION DISORDER; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEUROPATHY; PATHOPHYSIOLOGY; PSORIASIS; REVIEW; SKIN INFLAMMATION; SKIN NECROSIS; SPASTICITY;

CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; INTERFERONS; MULTIPLE SCLEROSIS;

EID: 0346348142     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. How interferons fight disease
2. Virus interference. I. The interferon
3. Interferons and their actions
4. TH1 and TH2 cells: Different pattern of cytokine secretion lead to different functional properties
5. Three-dimensional structure of recombinant interferon-gamma
6. The molecular cell biology of interferon-gamma and its receptor
7. Cytokines up-regulate la expression in organotypic cultures of central nervous system tissue
8. MHC class II molecules and autoimmunity
9. A molecular basis for MHC class II-associated autoimmunity
10. Contribution of a single DQ-chain residue to multiple sclerosis in French Canadians
11. Multiple sclerosis is associated with genes within or close to the HLA-DR-DQ subregion on a normal DR15, DQ6, Dw2 haplotype
12. Mental depression, acute infections in a patient treated with interferon-alpha
13. Oculomotor nerve paresis induced by alpha II-interferon
14. Acute third cranial nerve ophtalmoplegia: Possible pathogenesis from alpha-II-interferon treatment
15. Sudden hearing loss associated with interferon
16. Management of side-effects of beta-interferon therapy in MS
17. Neurotoxicity of interferon alpha
18. Suicide associated with alfa-interferon therapy for chronic viral hepatitis
19. Alpha interferon for induction of remission in hairy cell leukemia
20. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies. A review
21. Interferons in multiple sclerosis. A review of the evidence
22. Clinical trials of interferons in multiple sclerosis: What have we learned?
23. Clinical investigation of human alpha interferon in chronic myelogenous leukemia
24. Interferon therapy of relapsed and refractory Hodgkin's disease
25. Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: Clinical response and MRI/CSF findings
26. Randomized trial of interferon beta-1 a in chronic inflammatory demyelinating polyradiculoneuropathy
27. Toxic effect of intraventricular interferon-alfa in subacute sclerosis encephalitis
28. Intrathecal use of interferons in encephalitis
29. Interferon in the treatment of intracranial malignancies: A pilot study
30. Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis
31. Acyclovir monotherapy versus acyclovir plus beta-interferon in focal viral encephalitis in children
32. A case of chronic epileptic encephalopathy of neonatal onset. A probable concern of human cytomegalovirus
33. Alpha-interferon therapy in a case of probable progressive multifocal leukoencephalopathy
34. Interferon-alpha treatment in HTLV-I-associated myelopathy. Studies of clinical and immunological aspects
35. Recurrent herpes zoster myelitis treated with human interferon-alpha: A case report
36. A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma
37. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: A phase I-II study
38. Recombinant interferon beta: A phase I-II trial in children with recurrent brain tumors
39. Intraventricular alpha interferon therapy for Rasmussens syndrome
40. POEMS syndrome: An Italian case with diagnostic and therapeutic implications
41. A new scale for evaluating disability in multiple sclerosis
42. Raitieng neurologic impairment in multiple sclerosis; An Expanded Disability Status Scale (EDSS)
43. The current status of multiple sclerosis intra-blood-brain-barrier IgG synthesis
44. Interferon responses of leukocytes in multiple sclerosis
45. Studies of interferon production and natural killing by lymphocytes from multiple sclerosis patients
46. Interferon-β impairs induction of HLA-DR antigen expressin in cultured human astrocytes
47. Suppression of experimental allergic encephalomyelitis by interferon
48. Inhibition of passive localized experimental allergic encephalomyelitis by interferon
49. Suppressor cell function in multiple sclerosis: Correlation with clinical disease activity
50. Suppressor T-lymphocytes in multiple sclerosis: Analysis of patients with acute relapsing and chronic progressive disease
51. Interferon beta augments suppressor cell function in multiple sclerosis
52. Exacerbations of multiple sclerosis in patients treated with gamma interferon
53. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system
54. Systemic alpha interferon therapy in multiple sclerosis
55. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis
56. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: A double blind, placebo controlled trial
57. Effects of recombinant alpha-2b-interferon therapy in patients with progressive MS
58. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity and lymphocyte interferon gamma production in relapsing-remiting multiple sclerosis
59. A treatment for the chronic disabilities of stable multiple sclerosis
60. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation
61. Intrathecal interferon reduces exacerbations of multiple sclerosis
62. Intrathecal interferon in multiple sclerosis
63. Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon
64. Multicenter double-blind study of effect of intrathecally administered natural human fibroblast on exacerbations of multiple sclerosis
65. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis: Results of a multicenter double-blind study
66. Double blind study of intrathecal beta-interferon in multiple sclerosis: Clinical and laboratory results
67. Multiple sclerosis: Effect of intravenous natural beta interferon on clinical neurofunction, magnetic resonance imaging plaque burden, intrablood-brain barier IgG synthesis blood and cerebrospinal fluid cellular immunology and visual evoked responses
68. Recombinant human interferon beta treatment of relapsing-remiting multiple sclerosis: Pilot study results
69. Interferon beta-1b is effective in relapsing-remiting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
70. Interferon beta-1b is effective in relapsing-remiting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
71. Treatment of multiple sclerosis with interferons
72. Interferon B-1 a IM in multiple sclerosis RR
73. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron
74. In vivo effects of interferon beta-1 a on immunosuppressive cytokines in multiple sclerosis
75. Biodisponibility of recombinant human interferon β-1 a, after subcutaneous and intramuscular administration
76. Management of multiple sclerosis
77. Magnetic resonance studies of intramuscular interferon beta-1 a for relapsing multiple sclerosis
78. Interferon beta-1b treatment modulates TNFα and IFNγ spontaneous gene expression in MS
79. Natural killer cells in relapsing-remiting MS: Effect of treatment with interferon beta-1b